The efficacy and safety of teriparatide in advanced chronic kidney disease
Recruiting
- Conditions
- Osteoporosis, osteopenia
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Patients with chronic kidney disease stage 4 and 5 and meeting one of the following criteria
- Meeting criteria for the diagnosis of osteoporosis
- Trabecular bone score less than -2.0 and T score of bone mineral density more than -2.5 and less than -1.0
Exclusion Criteria
- Those on maintenance dialysis or expecting the initiation of dialysis within 2 years
- Those who had kidney transplantation
- Those on corticosteroid treatment, i.e. prednisolone equivalent dose more than 5mg a day
- Intact PTH 150 pg/mL and over
- Bone Paget disease
- Alkaline phosphatase twice the upper limit of reference range or over
- Previous radiation therapy to bones
- Hypercalcemia
- Primary bone malignancy or metastatic bone malignancy
- Allergy to teriparatide
- Pregnant women
- Previous therapy with teriparatide
Study & Design
- Study Type
- Interventional
- Study Design
- single assignment
- Primary Outcome Measures
Name Time Method - Increase in trabecular bone score in lumbar spine bone mineral density after 2 years
- Secondary Outcome Measures
Name Time Method Trabecular volumetric bone mineral densities Measured by 3D SHAPER
Cortical volumetric bone mineral densities Measured by 3D SHAPER
Bone mineral densities Measured by 3D SHAPER